Q-omics provides the consensus-scored ANKRD28 profile across patient tissues and cancer cell-line models. ANKRD28 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ANKRD28 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, ANKRD28 RNA expression shows 20,297 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, KIRC, and ACC as cancer lineages where ANKRD28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD28 survival associations across molecular data types. ANKRD28 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD28 RNA expression–survival associations across cancer types. High ANKRD28 expression shows unfavorable associations in MESO, PAAD and ACC, but favorable associations in HNSC, READ and BRCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ANKRD28 RNA expression.
This table summarizes ANKRD28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ANKRD28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD28 shows lower tumor expression in KIRC, THCA and LUSC and higher tumor expression in BLCA, LIHC and STAD. The KIRC box plot shows higher ANKRD28 RNA expression in normal versus tumor tissue (log2 FC = −0.655, t-test p < 0.001).
This table shows molecular features associated with ANKRD28 in patient tissues and cancer cell lines. In patient samples, ANKRD28 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD28 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
